Management Guideline for Dyslipidemias

Objectives

Standardise dyslipidaemia management in Belize using current scientific evidence to improve diagnosis, treatment and the quality of clinical and therapeutic care, while supporting prevention of cardiovascular disease through management of lipid abnormalities.[1]The guidance uses total cardiovascular risk to identify people most likely to benefit from preventive treatment and recognises that care should be individualised through clinical judgement rather than applied as a prescriptive pathway.[2][1]

• Reduce atherosclerotic cardiovascular risk by addressing elevated total cholesterol and low-density lipoprotein cholesterol through lifestyle measures and, where indicated, pharmacotherapy.[1][3]
• Prioritise people with established cardiovascular disease, diabetes with target-organ damage or microalbuminuria, chronic kidney disease, markedly elevated lipid levels, or multiple risk factors, who may be at high or very high risk without standard risk scoring.[2][4][5]
• Apply low-density lipoprotein cholesterol targets according to total risk, including below 1.8 mmol/L or a reduction of at least 50% from baseline for very-high-risk people, and consider below 3 mmol/L for people at moderate risk.[6]
• Promote diet, weight management, physical activity, smoking cessation and moderation or avoidance of alcohol as core measures for lipid control and cardiovascular prevention.[7][8][9]
• Address dyslipidaemia in population groups and clinical settings requiring tailored care, including children, women, older people, people with diabetes, metabolic syndrome, acute coronary syndrome, chronic kidney disease, stroke, and human immunodeficiency virus infection.[10][11][12][13][14][15]

Implementation

The guidance combines cardiovascular risk stratification, lipid testing, lifestyle support, pharmacological treatment and clinical follow-up. It was developed collaboratively by Belize’s Ministry of Health and the Pan American Health Organization, with contributions from multidisciplinary clinicians, the World Health Organization, and consultation with medical practitioners from Belize health regions.[16][1]Detailed governance arrangements, programme-level implementation responsibilities, financing and service-delivery plans are not specified.[16][1]

• Assess total cardiovascular risk using an established scoring approach, including Framingham where appropriate, alongside age, sex, blood pressure, smoking status, total cholesterol, high-density lipoprotein cholesterol and relevant clinical risk factors.[2][17]Interpret Framingham estimates cautiously because they predict coronary heart disease rather than all cardiovascular events and may not be calibrated to populations outside the United States.[4]
• Screen adults aged 20 years and over and people with relevant conditions or family history, including atherosclerosis, diabetes, hypertension, obesity, chronic kidney disease, suspected familial hypercholesterolaemia and antiretroviral therapy use.[5][18]Measure total cholesterol, triglycerides, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol at baseline, using direct low-density lipoprotein cholesterol measurement when triglycerides are elevated or a sample is non-fasting.[18][3]
• Deliver dietary advice that reduces saturated and trans fats, promotes unsaturated fats and soluble fibre, limits sugar, salt and cholesterol, and supports weight reduction and regular physical activity.[7][19][9]Consider selected functional foods or supplements, including phytosterols, soy protein, soluble fibre and fish oil, while recognising that evidence for long-term cardiovascular benefit is limited and product safety can vary.[20][19]
• Use statins as the principal pharmacological treatment for raised low-density lipoprotein cholesterol and consider fibrates, nicotinic acid, bile acid sequestrants, ezetimibe or omega-3 fatty acids according to lipid abnormality, cardiovascular risk, treatment tolerance and contraindications.[9][21][22][23]Use combination treatment cautiously because of interaction and adverse-effect risks, particularly myopathy with statin-fibrate combinations.[24][25][26]
• Manage severe hypertriglyceridaemia through calorie and fat restriction, alcohol abstinence, weight reduction, physical activity, glycaemic control where applicable, and triglyceride-lowering medicines to reduce acute pancreatitis risk.[23][27]
• Tailor treatment in specific groups, including diet-first management for childhood dyslipidaemia, individual assessment of older people, statin treatment in diabetes and chronic kidney disease where indicated, early high-dose statin treatment after acute coronary syndrome, and modification of therapy for drug interactions in people receiving antiretroviral treatment.[10][11][12][13][15]
• Monitor low-density lipoprotein cholesterol as the principal marker of response to lipid-lowering treatment and reassess treatment response after initiation or dose change, with subsequent clinical monitoring generally every 6 to 12 months.[6][15]Monitor liver enzymes during statin therapy and assess creatine kinase promptly when muscle symptoms occur or in people at high risk of myopathy.[21][15]
• Support adherence through clear written and oral instructions, treatment simplification, follow-up, individualised care, rapport-building and behavioural strategies.[15][28]

Monitoring & Evaluation

Monitoring is primarily clinical and treatment-focused: the guidance uses cardiovascular-risk stratification, lipid measurement, treatment-response assessment, safety testing, and follow-up to guide individual management. It does not establish a document-level programme monitoring framework, implementation indicators, reporting schedule, surveillance system, evaluation process, or institutional accountability mechanism.[29][15][28]

• Assess total cardiovascular risk with recognised scoring methods, including Framingham, to identify people likely to benefit from preventive treatment and classify coronary heart disease risk.[2][17]
• Classify Framingham 10-year risk as low below 10%, moderate from 10% to 20%, and high above 20%, while applying clinical judgement because estimates may not accurately predict risk in all populations or older people.[4][5]
• Measure baseline total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol; consider non-high-density lipoprotein cholesterol and lipid ratios where relevant.[18]
• Use fasting samples when assessing triglycerides or calculating low-density lipoprotein cholesterol through the Friedewald formula, and use direct low-density lipoprotein cholesterol measurement where triglycerides are high or samples are non-fasting.[18][3]
• Recognise variation in lipid results, including approximately 5% to 10% variation in total cholesterol and more than 20% variation in triglycerides, particularly in hypertriglyceridaemia.[18]
• Repeat lipid screening every four to six years for people aged 40 to 75 where low-density-lipoprotein-lowering therapy is not indicated.[5]
• Use low-density lipoprotein cholesterol as the principal marker of response to lipid-lowering treatment and as the main therapeutic target, reflecting its role in most lipid-lowering trials.[6]
• Assess high-density lipoprotein cholesterol assays against reference methods and control their performance through international quality programmes.[3]
• Monitor adherence to lifestyle change and compliance with treatment regimens as part of patient follow-up.[29]
• Review lipid levels four to six weeks after acute coronary syndrome to assess achievement of targets and whether treatment doses require adjustment for safety.[13]
• Assess response to statin therapy six to eight weeks after treatment initiation or a dose increase, recognising that fibrate and lifestyle responses may take longer; undertake subsequent monitoring every six to twelve months.[15]
• Monitor liver function periodically during statin treatment and investigate elevations above three times the upper limit of normal; discontinue statins if elevations persist, with cautious reintroduction potentially considered after normalisation.[21][15]
• Check creatine kinase for people at elevated risk of statin-related myopathy and immediately when muscle pain or weakness develops; stop treatment where levels exceed five times the upper limit of normal.[24][15]
• Monitor serum transaminases and uric acid every six to eight weeks during nicotinic-acid dose titration and every four to six months thereafter.[23]
• Monitor people receiving fibrates for myopathy, raised liver enzymes, cholelithiasis, gastrointestinal symptoms, rash, pruritus, and other adverse effects.[27]
• Evaluate dietary interventions through clinically relevant lipid concentrations and behavioural factors such as dietary intake, weight, alcohol consumption, smoking, and physical activity, although no formal evaluation procedure is defined.[7][8]
• Recognise evidence limitations: no specific trial targets are established for high-density lipoprotein cholesterol or triglycerides, and evidence for functional foods is generally weak because long-term dietary intervention trials are limited.[30][20]
• Support adherence through clear written and oral instructions, therapy tailored to patients' needs, behavioural strategies, regular follow-up, and exploration of barriers to treatment.[15][28]

Costing & Financing

No costs, medicine prices, budget allocations, financing sources, resource-mobilisation arrangements, funding gaps, costing methods, or economic assumptions are specified in the supplied extracts.[16][15][31]

• Require laboratory capacity for lipid testing, including direct low-density lipoprotein cholesterol measurement where appropriate, but the source does not quantify associated resource requirements or costs.[18][3]
• Require clinical follow-up and safety monitoring for lipid-lowering therapies, including liver-function and creatine-kinase testing in relevant circumstances, but no funding mechanism or budget is identified.[21][15]
• Include lifestyle, dietary, pharmacological, and specialised treatment approaches, but do not compare their affordability, cost-effectiveness, procurement requirements, or financial implications.[9][27][25]